Hepatitis: all 3,372 studies

Page 29 of 34. Open to participants first (195), then studies with results posted, then the rest; newest registration first within each.

• Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-InfectionCompletedNCT00879047Phase 1
• Augmenting Response to Entecavir With Peginterferon a-2a for the Treatment of HBeAg-positive Chronic Hepatitis BCompletedNCT00877760Phase 4
• Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination VaccineStatus unknownNCT00877357Phase 4
• Efficacy of Telbivudine Treatment at Long Term on the Absence of Liver Inflammation in Patients With Compensated Chronic Hepatitis BCompletedNCT00877149Phase 4
• Effects of Genotypes on Interferon Signaling in Chronic Hepatitis CWithdrawnNCT00876174
• Risk of Hepatitis B Virus Reactivation in Patients Undergoing AllograftingCompletedNCT00876148
• Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus InfectionTerminatedNCT00874796Phase 2
• Observational Study of Immune Response to Hepatitis B Childhood BoosterCompletedNCT00873652
• A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT00869661Phase 2
• Prediction of Hepatitis C Recurrence in Liver Transplant RecipientsTerminatedNCT00867243
• TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.CompletedNCT00866853Phase 1
• Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 WeeksWithdrawnNCT00862706Phase 4
• Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis BStatus unknownNCT00860626Not applicable
• A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis BCompletedNCT00857675Phase 3
• Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon ResistanceStatus unknownNCT00856804Phase 2
• A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNCT00854802Not applicable
• Antigen-specific Immune Response to Hepatitis B Virus in UteroStatus unknownNCT00845403
• Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral TreatmentCompletedNCT00844272Phase 4
• Impact of Hepatitis C Virus Variability on SteatosisTerminatedNCT00843076
• An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug UsersCompletedNCT00841477Phase 3
• Nutritional Support During Antiviral Therapy for Hepatitis CStatus unknownNCT00841243Phase 4
• Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced FibrosisTerminatedNCT00840489Phase 2
• Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune HepatitisCompletedNCT00838214Phase 2/3
• Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver TransplantationCompletedNCT00838071Phase 3
• Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular CarcinomaStatus unknownNCT00834860Phase 4
• Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCCCompletedNCT00834158Not applicable
• Autologous Bone Marrow Mononuclear Cells in Liver CirrhosisStatus unknownNCT00832247Phase 1
• High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3CompletedNCT00830609Phase 4
• VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy VolunteerCompletedNCT00828789Phase 1
• Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)CompletedNCT00828269Phase 1
• Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver CancerCompletedNCT00824707Not applicable
• Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT00823862Phase 1
• Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease PatientsStatus unknownNCT00823550Phase 4
• ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB TherapyTerminatedNCT00823342Phase 3
• Sonazoid Enhanced Liver Cancer Trial for Early DetectionStatus unknownNCT00822991Not applicable
• Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin InhibitorsCompletedNCT00819026
• A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis BStatus unknownNCT00815464Not applicable
• A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis CWithdrawnNCT00814606Phase 2
• Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)TerminatedNCT00811967Phase 3
• Study of Maternal Hepatitis C Infection and Influenza Vaccination in PregnancyTerminatedNCT00810875
• Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV InfectionStatus unknownNCT00810524Phase 4
• Vitamin D Treatment in Patients With Chronic Hepatitis CStatus unknownNCT00804752Not applicable
• Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)CompletedNCT00804622Phase 2
• Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 PatientsTerminatedNCT00803309Phase 4
• A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C PatientsCompletedNCT00801255Phase 1
• Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver TransplantationWithdrawnNCT00800787Phase 3
• A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis CCompletedNCT00800748Phase 4
• Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C VirusTerminatedNCT00800007Phase 1/2
• Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B PatientsTerminatedNCT00798460Phase 4
• A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)CompletedNCT00797745Phase 2
• Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver TransplantationCompletedNCT00794911Not applicable
• Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)CompletedNCT00788918Not applicable
• Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)CompletedNCT00787371Phase 2
• Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV InfectionCompletedNCT00782353Phase 1
• Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsWithdrawnNCT00782301Phase 4
• Hepatitis B and HIV Co-Infection in Patients in UgandaCompletedNCT00782158
• Antiviral Activity of AZD7295 in HCV CarriersCompletedNCT00781976Phase 1
• Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis BCompletedNCT00781105Phase 4
• Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis CCompletedNCT00778843Phase 3
• Prednisolone Priming Study in Patients With Chronic Hepatitis BStatus unknownNCT00778596Phase 4
• Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic InsufficiencyCompletedNCT00771446Phase 1/2
• Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral ReplicationCompletedNCT00769730
• Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular CarcinomaStatus unknownNCT00768157Phase 4
• Genetic Analysis of Liver CancerTerminatedNCT00768001
• Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular CarcinomaTerminatedNCT00767936
• 4-Week Lead-In With Nitazoxanide Followed by 36 Weeks Nitazoxanide and Peginterferon Alfa-2a in Chronic Hepatitis CCompletedNCT00763568Phase 2
• Increasing Hepatitis B Screening Among Korean Church AttendeesCompletedNCT00760721Phase 3
• Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C PatientsCompletedNCT00759200Phase 2
• Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral HepatitisTerminatedNCT00755950Phase 2/3
• Lifestyle Intervention Targetting Obesity and Insulin Resistance in Chronic Hepatitis CCompletedNCT00755742Not applicable
• A Phase II Study to Determine the Safety and Efficacy of Interferon-gamma in Patients With Chronic Hepatitis BStatus unknownNCT00753467Phase 2
• A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected AdultsCompletedNCT00752687Phase 1
• Treatment of Hepatitis C in Psychiatric PatientsCompletedNCT00751426
• Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical TherapyCompletedNCT00749138Phase 1
• Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV TherapyCompletedNCT00747539
• Hepatitis B Acceptability and Vaccination Incentive TrialCompletedNCT00744289Not applicable
• TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.CompletedNCT00741169Phase 1
• Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002)CompletedNCT00730431Phase 1
• Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)TerminatedNCT00727077
• Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C PatientsCompletedNCT00724776Phase 1
• PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)CompletedNCT00724620Phase 4
• Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)CompletedNCT00724295
• Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)CompletedNCT00724230
• Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206)TerminatedNCT00723879
• The Role of Dendritic Cells in Hepatitis C InfectionCompletedNCT00723242Not applicable
• A Multiple Ascending Dose Study of BMS-650032 in HCV Infected SubjectsCompletedNCT00722358Phase 2
• Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant PatientsCompletedNCT00722332Phase 4
• The Risk of Exacerbation of Chronic Hepatitis B After Percutaneous Radiofrequency Ablation of Hepatocellular CarcinomaStatus unknownNCT00720668
• Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis CCompletedNCT00718172Phase 1
• Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B PatientsWithdrawnNCT00715715Not applicable
• Assessment of Biomarkers for Recurrent HCV Infection Post-liver TransplantationCompletedNCT00710801
• Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis BWithdrawnNCT00710216Phase 4
• Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus InfectionCompletedNCT00707850Phase 4
• Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus InfectionCompletedNCT00707772Phase 4
• Chronic Hepatitis C and Insulin ResistanceCompletedNCT00707603
• An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)WithdrawnNCT00704756
• Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial RespondersCompletedNCT00704106
• HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C PatientsStatus unknownNCT00703872Phase 2
• Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV PatientsCompletedNCT00703560
• A Study of MDX-1106 to Treat Patients With Hepatitis C InfectionCompletedNCT00703469Phase 1

← Hepatitis overview